tbuckley/cabot-search huggingface dataset:
1292P A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)
Authors: G. Rousseau Bussac, F. Guisier, R. Veillon, H. Doubre, A.B. Cortot, L. Moreau, T. Pierret, L. Falchero, G. Justeau, C. Ricordel, H. Morel, K. Amrane, L. Bigay-Game, S. Hominal, S. Martinez, P.A. Renault, D. Moreau, M. Marcq, R. Descourt, L. Greillier
Journal: Annals of Oncology (2024)
1322P A phase II trial of autologous cytokine-induced killer (CIK) therapy plus toripalimab with or without chemotherapy as first-line treatment in advance NSCLC
Authors: B. Han, H. Zhong, R. Zhong, R. Qiao, J. Xu, W. Zhang, C. Shi, L. Xiong, S. Chen, M. Zhang
Journal: Annals of Oncology (2024)
1327P Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057
Authors: O. Honjo, T. Tozuka, Y. Tsukita, K. Kushiro, S. Hosokawa, M. Uematsu, T. Sumi, T. Naito, K. Ito, H. Wakui, H. Obata, T. Inoue, M. Kamimura, Y. Tsubata, D. Jingu, M. Sato, E. Miyauchi, S. Morita, K. Kobayashi, H. Asahina
Journal: Annals of Oncology (2024)
1294P Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry
Authors: A. Marinello, G. Massa, J. Rotow, H. Bote De Cabo, I. Monnet, F. Guisier, M. Duruisseaux, J.C. Benitez Montanez, J. Raimbourg, J. Costa, M. Tagliamento, J. Feng, A. Di Federico, G. Metro, F. Citarella, F. Tabbò, C. Lindsay, P. Iranzo Gomez, B. Besse, M. Aldea
Journal: Annals of Oncology (2024)
1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)
Authors: F. Citarella, M. Russano, M. Fiorenti, G. La Cava, E.G. Pizzutilo, F. Martinelli, S. Pierri, A. Russo, P. Muscolino, E. Sapuppo, A. Marinello, M. Aldea, B. Besse, M. Filetti, P. Lombardi, A. Vitale, F. Buzzacchino, L. Cristofani, A. Lugini, A. Cortellini
Journal: Annals of Oncology (2024)
1295P EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
Authors: E. Garralda, L. Clark, J.S. Wang, A.G. Gianoukakis, M.H. Taylor, D. Morgensztern, S.M. Arnold, D.R. Spigel, S.V. Liu, M.G. Krebs, M.D. Forster, J. Garcia-Corbacho, L.G. Paz-Ares, G. Fisher, S. Brook, S. Patel, H-T. Arkenau, B. Overstreet, G. Yalamanchili, P. Garrido Lopez
Journal: Annals of Oncology (2024)
1287P Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer
Authors: B.E. Jimenez Munarriz, S. Khan, K. Huenike, L. Eng, G. Liu, A.G. Sacher, P.A. Bradbury, N.B. Leighl, F.A. Shepherd
Journal: Annals of Oncology (2024)
1284P Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib
Authors: L. Robado de Lope, M.R. García Campelo, A. Azkárate Martínez, M. Cobo Dols, V. Calvo de Juan, E. Nadal, D. Rodriguez Abreu, A. Callejo Perez, M. Dómine Gómez, O.J. Juan Vidal, A. Collazo Lorduy, J. Mosquera Martinez, R. Marse Fabregat, P. Mediavilla Medel, R. Serna-Blasco, A. Romero, M. Provencio Pulla
Journal: Annals of Oncology (2024)
1286P Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients
Authors: C. Decroisette, R. Descourt, G. Rousseau Bussac, A. Swalduz, O. Bylicki, L. Bigay-Game, H. Doubre, A.B. Cortot, S. Hominal, L. Falchero, F. Guisier, M. Domblides, R. Lamy, J. Pinsolle, C. Ricordel, D. Moreau, S. Martinez, G. Justeau, C. Chouaid, L. Greillier
Journal: Annals of Oncology (2024)
1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
Authors: Y-L. Wu, H.R. Kim, R.A. Soo, Q. Zhou, H. Akamatsu, G-C. Chang, C.H. Chiu, H. Hayashi, S-W. Kim, Y. Goto, T. Kato, J. Zhou, V.H.F. Lee, M. Nishio, B. Han, D-W. Kim, S. Lu, A. Polli, J-F. Martini, T.S.K. Mok
Journal: Annals of Oncology (2024)
1285P Deep learning prediction of response to advanced-generation ALK inhibitors (aALKi) in ALK-rearranged advanced NSCLC (aNSCLC) patients using digital pathology
Authors: A. Stemmer, K. Parikh, Y-C. Lo, P. Shakya, W. Klaisuban, I. Vardi, D. Urban, H. Gantz Sorotsky, A. Onn, G. Kalmanovitz, E. Ofek, I. Barshack, J. Bar
Journal: Annals of Oncology (2024)
1276P EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status
Authors: C. Bennati, R. Ferrara, S. Sangaletti, S. Tamberi, A. Spadoni, G. Attisani, S. Zanuso, J. Longobardi, A. morigi, A. Zanichelli, P. Corsetto, M. Spreafico, C. Zingaretti, G. Mambelli, L. Turci, F. Fabbri, E. Carlotti, E. Fabbri, M. D'Arcangelo
Journal: Annals of Oncology (2024)
1282P Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naïve advanced ALK+ NSCLC from the ALTA-1L trial
Authors: L. Mezquita, J.C. Laguna Montes, M. Ferriol-Galmés, V.M. Albarran Artahona, M. García Pardo de Santayana, T. Gorría Puga, C. Crous Bruñol, M. Jiménez, M.B. Bernabeu Aracil, A.F. Navarro Mendivil, N. Reguart Aransay, A. Arcocha, C. Teixido, A-M.C. Dingemans, E. Auclin
Journal: Annals of Oncology (2024)
1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Authors: M.L. Reale, D. Scattolin, E. Bria, A. Vitale, S. Grisanti, J. Costa, D. Galetta, C. Sini, G. Minuti, F. Citarella, E. Roca, F. Agustoni, M. Tiseo, D.L. Cortinovis, S. Pilotto, S. Ricciardi, F. Passiglia, U. Malapelle, S. Novello, G. Pasello
Journal: Annals of Oncology (2024)
1274P Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform
Authors: L. Ugidos De La Varga, G. Hernández-Ibarburu, A. Parralejo Jimenez, J.D. Rodriguez-Castaño, J.J. Serrano, A. Ayuso, J. Rodriguez Pascual
Journal: Annals of Oncology (2024)
1278P Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
Authors: Y-K. Shi, J. Chen, R. Yang, H. Wu, Z. Wang, W. Yang, J. Cui, Y. Zhang, C. Liu, Y. Cheng, Y. Liu, J. Shan, D. Wang, L. Yang, C. Hu, M. Si, H. Li, L. Li, X. Kang, L. Wang
Journal: Annals of Oncology (2024)
1281P Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib
Authors: N. Heersche, D.A.C. Lanser, B. Muntinghe, M.I. Mohmaed Ali, E.B. Ulas, T.M.A. Trooster, E. de Jonge, E. Oomen-de Hoop, M.S. Paats, I. Bahce, S. Croes, L.E. Hendriks, A.J. Van Der Wekken, A-M.C. Dingemans, A.D.R. Huitema, R. Van Schaik, R.H. Mathijssen, M.G.D. Veerman
Journal: Annals of Oncology (2024)
1272P Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Authors: J-J. Yang, N. Pavlakis, F. Xie, T. Li, Y-L. Wu
Journal: Annals of Oncology (2024)
1280P Effects of semaglutide on the exposure of alectinib in patients with NSCLC
Authors: D.A.C. Lanser, N. Heersche, E. Oomen-de Hoop, A. Icli, P. de Bruijn, M.S. Paats, E. van Rossum, S.L. Koolen, R. Van Schaik, A-M.C. Dingemans, M.G.D. Veerman, R.H. Mathijssen
Journal: Annals of Oncology (2024)
1273P Risk factors for osimertinib-induced interstitial lung disease in patients with metastatic or recurrent non-small cell lung cancer harboring epidermal growth factor receptor mutations
Authors: S. Hori, T. Hase, F. Ushijima, S. Watanabe, H. Shibata, Y. Nakahara, K. Hayashi, H. Suzuki, T. Isobe, K. Ito, Y. Nanya, Y. Tsushima, R. Asaoka, M. Kagajo, H. Nakashima, T. Abe, M. Ando, T. Sashio, M. Ando, M. Ishii
Journal: Annals of Oncology (2024)
LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy
Authors: A. Botticelli, S. Scagnoli, P. Conte, C. Cremolini, P.A. Ascierto, F. Cappuzzo, M. Aglietta, F. Mazzuca, E. Capoluongo, G. Blandino, U. Malapelle, M. Nuti, G. D'Amati, B. Cerbelli, G. Pruneri, M. Biffoni, G. Giannini, F. Cognetti, G. Curigliano, P. Marchetti
Journal: Annals of Oncology (2024)
202P eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors
Authors: A.S. Truong, S.E. Thompson, R.K. Pavana, R.V. Changalvala, J.A. Sorrrentino, M.B. Friedersdorf
Journal: Annals of Oncology (2024)
174P Prognostic value of the immune and metabolic profile in the response to neoadjuvant treatment with ICIs in triple-negative breast cancer patients (TNBC)
Authors: L. Serrano García, G. Quintas, M. Pérez Álvarez de Lara, A. Moret, M. Portero Hernández, V. Iranzo, J.M. Cejalvo, J. García Sanchez, S. Marin Liebana, A. Llombart Cussac, L. Fernández-Murga
Journal: Annals of Oncology (2024)
210P Therapeutic implications of phosphoproteomics in molecular cancer diagnostics
Authors: A. Schneider, J. Woortman, C.B. Jensen, A. Sakhteman, F. Hamood, M-V. Teleanu, P. Horak, S. Kreutzfeldt, M. Resch, C. Stange, S.M. Pfister, O. Witt, D. Jones, M. The, D. Hübschmann, S. Fröhling, B. Kuster
Journal: Annals of Oncology (2024)
178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease
Authors: F. Miglietta, L. Nicolè, D. Iannaccone, T. Giarratano, D. Massa, G. Griguolo, C.A. Giorgi, A. Righetto, F. Girardi, C. Zurlo, F. Porra, F. Zanghi, G. Vernaci, M. Fassan, V. Guarneri, M.V. Dieci
Journal: Annals of Oncology (2024)
168P Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients
Authors: H. Grover, A. Kumar, M. Ks, P. Kumari, M. Patil, S. C, A. Chakraborty, J. Chauhan, R. Mandal, R. Sethia, S. Kulkarni, A. Tyagi, S. Kapoor, M.P. Castro, J. Wingrove
Journal: Annals of Oncology (2024)
225P Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
Authors: J. Tanizaki, K. Yonemori, Y. Takiguchi, K. Akiyoshi, K. Komine, Y. Onozawa, M. Sato, K. Hirata, T. Onoe, T. Ishiguro, A. Ito, Y. Chiba, H. Watanabe, Y. Togashi, K. Sakai, K. Nishio, K. Nakagawa, H. Hayashi
Journal: Annals of Oncology (2024)
173P Unveiling a novel EpCAM-CD24+ circulating cells with unidentified origin associated with breast cancer distant metastasis
Authors: E. Grigoryeva, L. Tashireva, V.V. Alifanov, O.E. Savelieva, E. Andruhova, M. Zavyalova, N. Cherdyntseva, V. Perelmuter
Journal: Annals of Oncology (2024)
319TiP NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
Authors: E. Bastien, B. Grandal, R. Sanchez, T. Ramtohul, D. Loirat, M.P. Sablin, A. Vincent-Salomon, J-Y. Pierga, F.C. Bidard, C. Malhaire, A. Savignoni, E. Romano
Journal: Annals of Oncology (2024)
198P Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
Authors: C.E. Heilig, M-V. Teleanu, A. Desuki, T. Kindler, B. Deschler, V. Kunzmann, N. von Bubnoff, L. Illert, D.T. Rieke, H. Süsse, L. Heiligenthal, S. Kreutzfeldt, P. Horak, K. Steindorf, A. Benner, D. Hübschmann, N. Schweigert, H. Glimm, S. Fröhling, R.F. Schlenk
Journal: Annals of Oncology (2024)
LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial
Authors: P.A. Fasching, D. Stroyakovskiy, D. Yardley, C-S. Huang, J.P. Crown, A. Bardia, S. Chia, S-A. Im, M. Martin Jimenez, B. Xu, S. Loi, C.H.E. Barrios, M. Untch, R. Moroose, F. Visco, G.N. Hortobagyi, D. Slamon, Y. Oviedo, S. Waters, S.A. Hurvitz
Journal: Annals of Oncology (2024)
186P Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis
Authors: D. Peh, Y. Low, C.J.L. Loh, J.K. Tay, J.P.S. Yeong, T.W.H. Shuen, C.M. Lim, S. Han, H.C. Toh
Journal: Annals of Oncology (2024)
1663TiP CYP11A1 inhibitor opevesostat (MK-5684) alone or in combination with other therapies for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): The phase I/II MK-5684-01A substudy
Authors: A. Hussain, C. Garratt, N. Li, Y. Liu, C.H. Poehlein, P.C. Fong
Journal: Annals of Oncology (2024)
167P Tumor-immune spatial interactions on NSCLC H&amp;E slide images predicts immunotherapy response: Preliminary external validation
Authors: L.I-Y. Chung, H. Li, L. Kim, S. Lee, O. Haji Maghsoudi, A. Hiremath, J. Lee, P. Haseok Kim, S. Lee, M. Yadav, M.J.A. Chuchuca, T. Um, Y. Kim, I. Hong, G. Kang, A. Cho, L. Cooper, A. Madabhushi, N. Braman, Y.K. Chae
Journal: Annals of Oncology (2024)
197P PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials
Authors: T.M. Kringelbach, L. Fagereng, S.F. Haj Mohammad, F. Verbeek, H.J.L. Timmer, T. Juslin, L. Verlingue, M.G. Krebs, J-Y. Blay, K. Jalkanen, K.S. Rohrberg, U.N. Lassen, A. Helland, H.M.W. Verheul, E.E. Voest, H. Gelderblom, K. Tasken
Journal: Annals of Oncology (2024)
LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
Authors: P. Schmid, H.L. McArthur, J. Cortés, B. Xu, F. Cardoso, M.L. Casalnuovo, U. Demirci, R. Freitas, J. Ghosh, R. Hegg, H. Iwata, Y.A. Lopez Chuken, M. Nechaeva, M.E. Robson, R. Villalobos Valencia, A. Lloyd, C. D'Cruz, A. Foxley, Y.H. Park
Journal: Annals of Oncology (2024)
318TiP Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study
Authors: F.M. Louis, A. van der Voort, C.P. Schröder, A.N. Scholten, J. Wesseling, M-J.T.F.D. Vrancken Peeters, R.M. Mann, G.S. Sonke
Journal: Annals of Oncology (2024)
176P ERBB2 amplifications across sex, race, and cancer types
Authors: M. Machaalani, R. El Hajj Chehade, A. Nassar, T. El Zarif, E. Saad, E. Yekeduz, R.M. Saliby, C. Steiner, R. Nawfal, K. Semaan, M. Eid, G-S.M. Lee, M. Pomerantz, R.R. McKay, P. Tarantino, D.A. Braun, M. Sun, S.M. Tolaney, T.K. Choueiri
Journal: Annals of Oncology (2024)
184P From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis
Authors: K. Egebjerg, K.S. Rohrberg, A. Bach Nielsen, M-L.M. Talman, A-V. Laenkholm, M. Nedergaard, R. Garbyal, J. Wang, F.M. Madsen, U.N. Lassen, A.S. Knop, I. Spanggaard, F. Bagger, M. Mann, M. Rossing, M. Mau-Sørensen
Journal: Annals of Oncology (2024)
LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
Authors: P. Schmid, J. Cortés, R.A. Dent, H.L. McArthur, L. Pusztai, S. Kummel, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, S-A. Im, M. Untch, P.A. Fasching, F. Cardoso, J. Zhao, X. Zhou, K.E. Tryfonidis, G. Aktan, J. O'Shaughnessy
Journal: Annals of Oncology (2024)
LBA11 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
Authors: I. Nederlof, A.L. Rolfes, R.C.A.M. Gielen, G. Awada, M.V. Dongen, H.M. Horlings, K. Van De Vijver, C.A. Drukker, F. van Duijnhoven, M. Lopez-Yurda, I. Mandjes, R.M. Mann, C.E. Loo, C.U. Blank, T.N. Schumacher, R.F. Salgado, M. Kok
Journal: Annals of Oncology (2024)
185P Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
Authors: M. Pouyiourou, G. Zaun, U.T. Hacker, T. Ernst, M. Stahl, P. Arni, H. Löffler, L. Möhrmann, A. Kumar, A. Brobeil, A. Stenzinger, T. Bochtler, A. Krämer
Journal: Annals of Oncology (2024)
172P HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd)
Authors: A. Ismail, M. Modi, A. Kleckley, M. Midhun, A. Basu, N. Jahan, G. Gupta, B. El-Rayes, T. Mattox, C. Hawkins, S. Bae, M. Akce, R. Arend, Y. Boumber, A. Desai
Journal: Annals of Oncology (2024)
180P FIRE-6: Longitudinal immune profiling identified disturbed NK cell functionality in RAS/BRAF wild-type metastatic colorectal cancer patients and during combined treatment with FOLFIRI, cetuximab followed by avelumab maintenance
Authors: P. Schiele, S. Kolling, S. Stintzing, C. Junkuhn, A. Walter, S. Rosnev, J. von Einem, W. Schöning, I. Sauer, D.P. Modest, K. Heinrich, L. Weiss, L. Bullinger, M. Frentsch, V. Heinemann, I-K. Na
Journal: Annals of Oncology (2024)
LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)
Authors: A. De Caluwe, I. Desmoulins, K. Cao, V. Remouchamps, A. Baten, E. Longton, K. Peignaux-Casasnovas, G. Nader-Marta, L. Arecco, E. Agostinetto, P. Kristanto, X. Catteau, D. Larsimont, R.F. Salgado, C. Sotiriou, P. Poortmans, M. Piccart, M. Ignatiadis, E. Romano, L. Buisseret
Journal: Annals of Oncology (2024)
LBA14 Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
Authors: S. Linn, R.L. Seefat, V. De Jong, S.B. Vliek, S. Balduzzi, R.M. Bijlsma, M. Jongen-Lavrencic, I. Mandjes, M. Delfos, M. Schot, M.M. van Rosmalen, V. Retel, I. Eekhout, E. Kuip, A. Gonçalves, J. Nuver, M. Wymenga, I.R. Konings, V. Tjan-Heijnen, A. Jager
Journal: Annals of Oncology (2024)
Update on Whole-body MRI Surveillance for Pediatric Cancer Predisposition Syndromes
Authors: Mary-Louise C. Greer, Lisa J. States, David Malkin, Stephan D. Voss, Andrea S. Doria
Journal: Clinical Cancer Research (2024)

Abstract Whole-body MRI (WBMRI) is an integral part of screening infants, children and adolescents for pre-symptomatic neoplasms in certain cancer predisposition syndromes (CPS). This includes Li-Fraumeni and Constitutional Mismatch Repair Deficiency syndromes, among others. The list of syndromes where WBMRI adds value, as part of a comprehensive surveillance protocol, continues to evolve in response to new evidence, growing experience and more widespread adoption of WBMRI. In July 2023, the American Association of Cancer Research (AACR) reconvened an international, multidisciplinary panel to revise and update recommendations stemming from the 2016 AACR Special Workshop on Childhood Cancer Predisposition. That initial meeting resulted in a series of publications in Clinical Cancer Research in 2017, including “Pediatric Cancer Predisposition Imaging: Focus on Whole Body MRI”. This 2024 review of WBMRI in CPS updates the 2017 WBMRI publication, the revised recommendations derived from the 2023 AACR Childhood Cancer Predisposition Workshop based on available data, societal guidelines and expert opinion. Different aspects of acquiring and interpreting WBMRI including diagnostic accuracy are discussed. Application of WBMRI in resource poor environments, as well as integration of whole-body imaging techniques with emerging technologies such as cell-free DNA, or liquid biopsies, and artificial intelligence/machine learning are also considered.
798TiP Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial
Authors: S. Banerjee, A. Taylor, J. Bliss, J. Stewart, L. Smith, L. Moretti, L. Kilburn, L. Finneran
Journal: Annals of Oncology (2024)
691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Authors: A.M. Schram, G. Lopes, A.B. El-Khoueiry, E. Fontana, T.B. Karasic, S. Kummar, P. Lorusso, V. Gregorc, M. Millward, S. Ponce Aix, D.L. Richardson, D. Roda Perez, A.I. Spira, D.S. Tan, J.A. Thompson, D. Uprety, M. Fellous, Y.G. Qin, E.E. Dumbrava
Journal: Annals of Oncology (2024)
601TiP A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Authors: I. Pokataev, A. Tryakin, M. Fedyanin, T. Antonova, A. Semenova, A. Lebedeva, O.A. Kuznetsova, E. Veselovsky, M. Ivanov, V. Mileyko, M. Byakhov, M. Biakhova, V. Galkin
Journal: Annals of Oncology (2024)
708P The Empower Pathway: An audit of the first 150 patients. Enhanced personalised care of testicular cancer survivors
Authors: P. Champion, R. Holwell, R.A. Huddart, D. Nicol, A. Reid, W. Cazzaniga, N. Kinsella, C. Kirk, M. Miletic, M. Drain
Journal: Annals of Oncology (2024)
793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Authors: D. Lorusso, M.R. Mirza, J. Martin-Babau, A. Bologna, M.P. Barretina Ginesta, F. Marmé, J. Wampfler, D. Cibula, J. Zhu, K. Hasegawa, V. Samouëlian, J-Y. Lee, F.C. Casarotto, Y. Antill, M. Lightfoot, T.J. Herzog, K. Woodhouse, Y. Cui, B.M. Slomovitz, B.J. Monk
Journal: Annals of Oncology (2024)
690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Authors: T.B. Powles, A.K. Bhatia, B. Burtness, T. Kogawa, T. Nishina, I. Nakayama, C. Fountzilas, D.R. Castillo, M. Mckean, F. Meric-Bernstam, N. Colombo, J.W. Smithy, J. Fayette, S. Chandra, D.W. Sternberg, K.H. Sullivan, S. Yueh, G. Clinthorne, R. Kudchadkar, H. Hayashi
Journal: Annals of Oncology (2024)
602TiP Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Authors: J. Huang, F. He, Y. Zhao, G. Cai, P. Liu, Z. Liu, R. Zhang, Y.H. Gao, Y. Tang, Y. Ju, F. Xia, W. Han, J. Bai, L. Han, Z. Liu, F. Pei, Q. Yao, Q. Lv, P. Liu
Journal: Annals of Oncology (2024)
1135P Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma
Authors: M. Haist, M. Matusiak, Y. Tan, S. Zimmer, H. Stege, S. Mitschke, B. Weidenthaler-Barth, A. Delgado-Gonzalez, M.A. Baertsch, F. Rogall, Y. Goltsev, S. Grabbe, J. Hickey, G. Nolan
Journal: Annals of Oncology (2024)
1134P Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
Authors: C. Lebbe, P. Nghiem, S. Bhatia, L. Mortier, A.S. Brohl, N. Jacob, K. Tyroller, J. Hoffman, S.P. D'Angelo
Journal: Annals of Oncology (2024)
790P The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
Authors: C. Garcia Duran, L. Musacchio, R. Mazzeo, L. Carità, J. Jimenez, J.F. Grau Béjar, D.G. Illescas, R. Fasani, L. Fariñas Madrid, G. Villacampa, A. Oaknin
Journal: Annals of Oncology (2024)
1252P Stage III non-small cell lung cancer (NSCLC) in France, characteristics treatments and survival results of French real-world data
Authors: O. Molinier, I. Monnet, O. Bylicki, L. Moreau, M. Fore, R. Corre, L. Portel, R. Chikouche, H. Francois, C. Dayen, C. Rizzo, M. Tiercin, F. El Khanjari, J. Obert, P. Beynel, C. Dujon, H. Ghalloussi-Tebai, C. Alizon, A-S. Bugnet, D. Debieuvre
Journal: Annals of Oncology (2024)